ZBH Zimmer Biomet Holdings Inc

Price (delayed)

$108.87

Market cap

$22.82B

P/E Ratio

103.69

Dividend/share

$0.96

EPS

$1.05

Enterprise value

$28.68B

Zimmer Biomet is a publicly traded medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of ...

Highlights
The debt has declined by 20% year-on-year and by 11% since the previous quarter
ZBH's quick ratio is down by 38% YoY but it is up by 34% QoQ
Zimmer Biomet Holdings's gross profit has increased by 12% YoY but it has decreased by 3.1% from the previous quarter
The EPS has plunged by 62% YoY and by 46% from the previous quarter
The net income has dropped by 62% year-on-year and by 46% since the previous quarter

Key stats

What are the main financial stats of ZBH
Market
Shares outstanding
209.58M
Market cap
$22.82B
Enterprise value
$28.68B
Valuations
Price to earnings (P/E)
103.69
Price to book (P/B)
1.9
Price to sales (P/S)
2.98
EV/EBIT
65.74
EV/EBITDA
19.53
EV/Sales
3.75
Earnings
Revenue
$7.65B
EBIT
$436.3M
EBITDA
$1.47B
Free cash flow
$1.02B
Per share
EPS
$1.05
Free cash flow per share
$4.9
Book value per share
$57.44
Revenue per share
$36.58
TBVPS
$35.04
Balance sheet
Total assets
$21.62B
Total liabilities
$9.6B
Debt
$6.3B
Equity
$12.02B
Working capital
$1.84B
Liquidity
Debt to equity
0.52
Current ratio
1.69
Quick ratio
0.63
Net debt/EBITDA
3.99
Margins
EBITDA margin
19.2%
Gross margin
69.6%
Net margin
2.8%
Operating margin
9.3%
Efficiency
Return on assets
0.9%
Return on equity
1.7%
Return on invested capital
3.7%
Return on capital employed
2.3%
Return on sales
5.7%
Dividend
Dividend yield
0.88%
DPS
$0.96
Payout ratio
91.4%

ZBH stock price

How has the Zimmer Biomet Holdings stock price performed over time
Intraday
2.32%
1 week
6.06%
1 month
-8.81%
1 year
-33.77%
YTD
-14.3%
QTD
-14.88%

Financial performance

How have Zimmer Biomet Holdings's revenue and profit performed over time
Revenue
$7.65B
Gross profit
$5.33B
Operating income
$712.9M
Net income
$217.7M
Gross margin
69.6%
Net margin
2.8%
The net margin has dropped by 66% year-on-year and by 45% since the previous quarter
The net income has dropped by 62% year-on-year and by 46% since the previous quarter
Zimmer Biomet Holdings's operating income has increased by 14% YoY but it has decreased by 9% QoQ
Zimmer Biomet Holdings's gross profit has increased by 12% YoY but it has decreased by 3.1% from the previous quarter

Growth

What is Zimmer Biomet Holdings's growth rate over time

Valuation

What is Zimmer Biomet Holdings stock price valuation
P/E
103.69
P/B
1.9
P/S
2.98
EV/EBIT
65.74
EV/EBITDA
19.53
EV/Sales
3.75
The EPS has plunged by 62% YoY and by 46% from the previous quarter
ZBH's P/E is 59% higher than its last 4 quarters average of 65.3
The stock's P/B is 21% below its last 4 quarters average of 2.4 and 14% below its 5-year quarterly average of 2.2
ZBH's equity is down by 5% since the previous quarter and by 3.5% year-on-year
ZBH's price to sales (P/S) is 22% lower than its last 4 quarters average of 3.8 and 15% lower than its 5-year quarterly average of 3.5
The revenue has grown by 12% YoY but it has contracted by 2.4% from the previous quarter

Efficiency

How efficient is Zimmer Biomet Holdings business performance
Zimmer Biomet Holdings's return on equity has shrunk by 64% YoY and by 47% QoQ
The ROA has plunged by 63% YoY and by 47% from the previous quarter
The ROS has contracted by 41% YoY and by 29% from the previous quarter
The ROIC has decreased by 27% QoQ and by 27% YoY

Dividends

What is ZBH's dividend history
DPS
$0.96
Dividend yield
0.88%
Payout ratio
91.4%
Recent dividends

Financial health

How did Zimmer Biomet Holdings financials performed over time
The total assets is 125% higher than the total liabilities
ZBH's quick ratio is down by 38% YoY but it is up by 34% QoQ
The current ratio has contracted by 29% YoY but it has grown by 20% from the previous quarter
The debt is 48% smaller than the equity
The debt has declined by 20% year-on-year and by 11% since the previous quarter
The debt to equity has declined by 17% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.